[First somatic human gene therapy in the USA approved].
The clinical protocol to treat infants with severe combined immuno deficiency due to adenosine deaminase (ADA) deficiency by means of gene thereapy has been approved recently. The Human Gene Therapy Subcommittee and the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) concluded the review on July 30th and opened the door for the first federally approved somatic Human Gene Therapy.
Meran
J G
JG
D000243:Adenosine Deaminase / Q000172:deficiency*; D004992:Ethics, Medical; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008661:Metabolism, Inborn Errors / Q000628:therapy*; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D014481:United States
D000243:Adenosine Deaminase
Erste somatische Human-Gentherapie in den USA genehmigt.